GTx Inc. (GTXI)

18.89
NASDAQ : Health Technology
Prev Close 18.89
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.73 / 23.40
Avg Volume 130.50K
Exchange NASDAQ
Shares Outstanding 22.53M
Market Cap 439.11M
EPS -1.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Small-Cap Stocks Are Doing Something They Haven't Done Consistently in 3 Years

Small-Cap Stocks Are Doing Something They Haven't Done Consistently in 3 Years

Small-cap stocks have finally jumped back to life on prospects for a strong U.S. economy this year. What trade war?

GTx Provides Corporate Update And Reports Fourth Quarter And Full Year 2017 Financial Results

GTx Provides Corporate Update And Reports Fourth Quarter And Full Year 2017 Financial Results

GTx, Inc. (Nasdaq:GTXI) today reported financial results for the fourth quarter and year ended December 31, 2017 and highlighted recent accomplishments and upcoming milestones.

GTx Announced New Data Demonstrating Enobosarm's Potential To Treat Stress Urinary Incontinence At SUFU 2018

GTx Announced New Data Demonstrating Enobosarm's Potential To Treat Stress Urinary Incontinence At SUFU 2018

GTx, Inc. (Nasdaq:GTXI) today announced additional results from a Phase 2 proof-of-concept clinical trial of 3 mg enobosarm administered orally in postmenopausal women with stress urinary incontinence (SUI), including...

GTx Phase 2 Enobosarm Clinical Trial Results In Stress Urinary Incontinence Accepted For Podium Presentation At SUFU

GTx Phase 2 Enobosarm Clinical Trial Results In Stress Urinary Incontinence Accepted For Podium Presentation At SUFU

GTx, Inc. (Nasdaq: GTXI) today announced the acceptance of an abstract on clinical results from an ongoing, open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm 3 mg in postmenopausal women with stress...

GTx Provides Corporate Update And Reports Third Quarter 2017 Financial Results

GTx Provides Corporate Update And Reports Third Quarter 2017 Financial Results

GTx, Inc. (Nasdaq:GTXI) today reported financial results for the third quarter of 2017 and highlighted recent accomplishments and upcoming milestones.

GTx, Inc. To Participate In The Stifel 2017 Healthcare Conference

GTx, Inc. To Participate In The Stifel 2017 Healthcare Conference

GTx, Inc. (Nasdaq: GTXI) today announced that Robert J.

GTx Announces Closing Of $48.5 Million Private Placement

GTx Announces Closing Of $48.5 Million Private Placement

GTx, Inc. (NASDAQ: GTXI) today announced that it has closed the previously-announced private placement of its common stock and warrants to purchase its common stock.

GTx Announces $48.5 Million Private Placement

GTx Announces $48.5 Million Private Placement

GTx, Inc. (NASDAQ: GTXI) today announced that it has entered into a definitive securities purchase agreement for the sale of its common stock and warrants to purchase common stock in a private placement that is...

GTx Announces Webcast Of Corporate Presentation At The 2017 Cantor Fitzgerald Global Healthcare Conference

GTx Announces Webcast Of Corporate Presentation At The 2017 Cantor Fitzgerald Global Healthcare Conference

GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on September 27, 2017, at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York City.

GTx To Host Key Opinion Leader Luncheon On The Topic Of Stress Urinary Incontinence On September 28th In New York City

GTx To Host Key Opinion Leader Luncheon On The Topic Of Stress Urinary Incontinence On September 28th In New York City

GTx, Inc. (Nasdaq: GTXI) today announced that it will be hosting and simultaneously webcasting a Key Opinion Leader (KOL) luncheon meeting on the topic of Stress Urinary Incontinence (SUI) on Thursday, September 28 th in...

GTx Announces Positive Results From Enobosarm Phase 2 Proof-of-Concept Clinical Trial In Women With Stress Urinary Incontinence

GTx Announces Positive Results From Enobosarm Phase 2 Proof-of-Concept Clinical Trial In Women With Stress Urinary Incontinence

GTx, Inc. (Nasdaq: GTXI) today announced top-line clinical trial results demonstrating that a daily dose of enobosarm 3 mg (GTx-024) substantially improved stress urinary incontinence (SUI) in women, as well as related...

GTx Provides Corporate Update And Reports Second Quarter 2017 Financial Results

GTx Provides Corporate Update And Reports Second Quarter 2017 Financial Results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the second quarter of 2017 and highlighted recent accomplishments and upcoming milestones.

GTx Announces Positive Preliminary Results From Ongoing Phase 2 Proof-of-Concept Clinical Trial In Women With Stress Urinary Incontinence

GTx, Inc. (Nasdaq: GTXI) today announced release of preliminary clinical data from its ongoing, open-label, Phase 2 clinical trial of enobosarm 3 mg (GTx-024) in postmenopausal women with stress urinary incontinence (SUI).

GTx Provides Corporate Update And Reports First Quarter 2017 Financial Results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the first quarter of 2017, and highlighted recent accomplishments and upcoming milestones.

GTx Announces Acceptance Of An Abstract On Preliminary Results From Phase 2 Clinical Trial In Women With Stress Urinary Incontinence At The International Continence Society Annual Meeting

GTx, Inc. (Nasdaq: GTXI) today announced the acceptance of an abstract on preliminary clinical data from its ongoing, open-label, Phase 2 proof-of-concept clinical trial of enobosarm (GTx-024) evaluating enobosarm 3 mg in...

GTx Announces Results From Preclinical Studies Of SARMs In Duchenne Muscular Dystrophy Models Published In Human Molecular Genetics

GTx, Inc. (Nasdaq: GTXI) today announced the publication in the journal Human Molecular Genetics of results from preclinical studies supporting the potential efficacy of the Company's SARMs, and in particular GTx-026, for...

GTx Provides Corporate Update And Reports Fourth Quarter And Year-End 2016 Financial Results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the fourth quarter and year ended December 31, 2016, and highlighted recent accomplishments and upcoming milestones.

GTx, Inc. To Report Fourth Quarter And Full Year 2016 Financial Results On March 15, 2017

GTx, Inc. (NASDAQ: GTXI) today announced that the timing for its fourth quarter and full year 2016 financial results press release will be Wednesday, March 15, 2017, prior to the opening of the U.

GTx Reports Results From Ongoing Enobosarm Phase 2 Clinical Trial In ER+/AR+ Breast Cancer

GTx Reports Results From Ongoing Enobosarm Phase 2 Clinical Trial In ER+/AR+ Breast Cancer

GTx, Inc. (Nasdaq: GTXI) announced today positive initial data from its ongoing open-label enobosarm Phase 2 clinical trial in women with advanced, estrogen receptor positive (ER+), androgen receptor positive (AR+) breast...

GTx, Inc. Announces 1-for-10 Reverse Stock Split

GTx, Inc. Announces 1-for-10 Reverse Stock Split

GTx, Inc. (Nasdaq: GTXI) today announced a reverse stock split of its shares of common stock at a ratio of one-for-ten.

Enobosarm Meets Pre-Specified Primary Efficacy Endpoint In Ongoing Phase 2 Clinical Trial In ER+/AR+ Breast Cancer

Enobosarm Meets Pre-Specified Primary Efficacy Endpoint In Ongoing Phase 2 Clinical Trial In ER+/AR+ Breast Cancer

GTx, Inc. (Nasdaq: GTXI) today announced that enobosarm achieved the pre-specified primary efficacy endpoint in the 9 mg dose cohort from patients in both stage 1 and the ongoing stage 2 of its Phase 2 clinical trial in...

GTx Announces Webcast Of Corporate Presentation At The 28th Annual Piper Jaffray Healthcare Conference

GTx Announces Webcast Of Corporate Presentation At The 28th Annual Piper Jaffray Healthcare Conference

GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on November 30, 2016, at the 28 th Annual Piper Jaffray Healthcare Conference in New York City.

GTx Achieves Second Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer

GTx Achieves Second Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer

GTx, Inc. (Nasdaq: GTXI) today announced the achievement of the Stage 1 milestone for the 18 mg cohort of its Phase 2 clinical trial of enobosarm (GTx-024) to treat women with advanced, estrogen receptor positive (ER+),...

GTx Announces Webcast Of Corporate Presentation At The Stifel 2016 Healthcare Conference

GTx Announces Webcast Of Corporate Presentation At The Stifel 2016 Healthcare Conference

GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on November 16, 2016, at the Stifel 2016 Healthcare Conference in New York City.

GTx Provides Corporate Update And Reports Third Quarter 2016 Financial Results

GTx Provides Corporate Update And Reports Third Quarter 2016 Financial Results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the third quarter ended September 30, 2016 and provided an update on the Company's clinical development activities.

GTx Announces $14.0 Million Registered Direct Common Stock Offering

GTx Announces $14.0 Million Registered Direct Common Stock Offering

GTx, Inc. (NASDAQ: GTXI) today announced that it has entered into definitive agreements with certain existing shareholders of the Company, including J.

GTx Achieves Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer

GTx Achieves Stage 1 Milestone In Phase 2 Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer

GTx, Inc. (Nasdaq: GTXI) today announced the achievement of the Stage 1 milestone for the 9 mg cohort of its Phase 2 clinical trial of enobosarm (GTx-024) to treat women with advanced, estrogen receptor positive (ER+),...

GTx Announces Webcast Of Corporate Presentation At Baird's 2016 Healthcare Conference

GTx Announces Webcast Of Corporate Presentation At Baird's 2016 Healthcare Conference

GTx, Inc. (Nasdaq: GTXI) announced today that management will present a company overview on September 8, 2016, at the Baird 2016 Healthcare Conference in New York City.